The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis
Open accessAbstract
SUMMARY Dysregulation of the gut microbiome has been implicated in the progression of nonalcoholic fatty liver disease (NAFLD) to advanced fibrosis and cirrhosis. To determine the diagnostic capacity of this association, stool microbiomes were compared across 163 well-characterized participants encompassing non-NAFLD controls, NAFLD-cirrhosis patients and their first-degree relatives. Interrogation of shotgun metagenomic and untargeted metabolomic profiles using the Random Forest machine learning algorithm and differential abundance analysis identified discrete metagenomic and metabolomic signatures that were similarly effective in detecting cirrhosis (diagnostic accuracy 0.91, AUC). Combining the metagenomic signature with age and serum albumin levels accurately distinguished cirrhosis in etiologically and genetically distinct cohorts from geographically separated regions. Additional inclusion of serum aspartate aminotransferase levels, which are increased in cirrhosis patients, enabled discrimination of cirrhosis from earlier stages of fibrosis. These findings demonstrate that a core set of gut microbiome species may offer universal utility as a non-invasive diagnostic test for cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide and is estimated to affect 24% of the global population (Loomba and Sanyal, 2013; Younossi et al., 2018).”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis
Tsugawa, H., Cajka, T., Kind, T., Ma, Y., Higgins, B., Ikeda, K., Kanazawa, M., VanderGheynst, J., Fiehn, O., & Arita, M. (2015) · Nature Methods · doi:10.1038/nmeth.3393 · Cited by 3,397
Alterations of the human gut microbiome in liver cirrhosis
Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., Guo, J., Le Chatelier, E., Yao, J., Wu, L., et al. (2014) · Nature · doi:10.1038/nature13568 · Cited by 2,177
Self-citationAn integrated catalog of reference genes in the human gut microbiome
MetaHIT Consortium, Li, J., Jia, H., Cai, X., Zhong, H., Feng, Q., Sunagawa, S., Arumugam, M., Kultima, J. R., Prifti, E., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2942 · Cited by 2,164
Metagenomic microbial community profiling using unique clade-specific marker genes
Segata, N., Waldron, L., Ballarini, A., Narasimhan, V., Jousson, O., & Huttenhower, C. (2012) · Nature Methods · doi:10.1038/nmeth.2066 · Cited by 1,776 · cited 2×
“…of the microbial communities and the abundance of microbial pathways were determined from shotgun sequencing of stool samples using Metagenomic Phylogenetic Analysis (MetaPhlAn2, (Segata et al., 2012) and HMP Unified Metabolic Analysis Network 2 (HUMAnN2, (Franzosa et al., 2018) respectively.”
MethodSpecies-level functional profiling of metagenomes and metatranscriptomes
Franzosa, E. A., McIver, L. J., Rahnavard, G., Thompson, L. R., Schirmer, M., Weingart, G., Lipson, K. S., Knight, R., Caporaso, J. G., Segata, N., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0176-y · Cited by 1,693
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Self-citationA gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites
Dodd, D., Spitzer, M. H., Van Treuren, W., Merrill, B. D., Hryckowian, A. J., Higginbottom, S. K., Le, A., Cowan, T. M., Nolan, G. P., Fischbach, M. A., et al. (2017) · Nature · doi:10.1038/nature24661 · Cited by 1,425
Cited by
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationGut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Intestinal Barrier in Human Health and Disease
Di Tommaso, N., Gasbarrini, A., & Ponziani, F. R. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312836 · Cited by 533
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 507
Behary, J., Amorim, N., Jiang, X.-T., Raposo, A., Gong, L., McGovern, E., Ibrahim, R., Chu, F., Stephens, C., Jebeili, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20422-7 · Cited by 470
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Gut–liver axis: barriers and functional circuits
Pabst, O., Hornef, M. W., Schaap, F. G., Cerovic, V., Clavel, T., & Bruns, T. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00771-6 · Cited by 436
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
Role of the gut microbiota in type 2 diabetes and related diseases
Yang, G., Wei, J., Liu, P., Zhang, Q., Tian, Y., Hou, G., Meng, L., Xin, Y., & Jiang, X. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154712 · Cited by 418
The role of hepatokines in NAFLD
Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H.-U., & White, M. F. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.006 · Cited by 282
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 268
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationThe intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Sharpton, S. R., Schnabl, B., Knight, R., & Loomba, R. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.11.010 · Cited by 194
Self-citationRisk assessment with gut microbiome and metabolite markers in NAFLD development
Leung, H., Long, X., Ni, Y., Qian, L., Nychas, E., Siliceo, S. L., Pohl, D., Hanhineva, K., Liu, Y., Xu, A., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abk0855 · Cited by 152
“We also examined whether the selected features in the model were biologically relevant to NAFLD development by exploring the diagnostic power of the model in several case-control cohorts from Asia, the United States, and Europe.”
BackgroundMethodInfluentialSelf-citationThe Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology · doi:10.1002/hep.31523 · Cited by 88
Self-citationGut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease
Raya Tonetti, F., Eguileor, A., Mrdjen, M., Pathak, V., Travers, J., Nagy, L. E., & Llorente, C. (2024) · Hepatology · doi:10.1097/hep.0000000000000924 · Cited by 78
Rational combination therapy for NASH: Insights from clinical trials and error
Ratziu, V., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.025 · Cited by 71
Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies
Koning, M., Herrema, H., Nieuwdorp, M., & Meijnikman, A. S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2226922 · Cited by 56
Carter, J. K., Bhattacharya, D., Borgerding, J. N., Fiel, M. I., Faith, J. J., & Friedman, S. L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0244763 · Cited by 52
Nassar, M., Rogers, A. B., Talo', F., Sanchez, S., Shafique, Z., Finn, R. D., & McEntyre, J. (2022) · GigaScience · doi:10.1093/gigascience/giac077 · Cited by 13
Metadata
- Authors
- Oh, T. G., Kim, S. M., Caussy, C., Fu, T., Guo, J., Bassirian, S., Singh, S., Madamba, E. V., Bettencourt, R., Richards, L., Yu, R. T., Atkins, A. R., Huan, T., Brenner, D. A., Sirlin, C. B., Downes, M., Evans, R. M., & Loomba, R.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 32
- Issue
- 5
- Pages
- 878-888.e6
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W3040384889
- Cited by
- 334
- References
- 48
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.